Barclays PLC Raises Stake in Arvinas, Inc. (NASDAQ:ARVN)

Barclays PLC raised its stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 43.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 175,019 shares of the company's stock after buying an additional 53,320 shares during the period. Barclays PLC owned about 0.25% of Arvinas worth $3,354,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ARVN. Franklin Resources Inc. boosted its holdings in Arvinas by 11.6% in the third quarter. Franklin Resources Inc. now owns 69,190 shares of the company's stock valued at $1,776,000 after acquiring an additional 7,166 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Arvinas by 18.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock worth $57,371,000 after purchasing an additional 367,343 shares during the period. Nordea Investment Management AB boosted its stake in shares of Arvinas by 4.1% in the 4th quarter. Nordea Investment Management AB now owns 232,886 shares of the company's stock valued at $4,404,000 after purchasing an additional 9,196 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Arvinas by 0.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company's stock worth $2,694,000 after buying an additional 777 shares during the period. Finally, SG Americas Securities LLC raised its stake in Arvinas by 228.8% during the fourth quarter. SG Americas Securities LLC now owns 32,424 shares of the company's stock worth $622,000 after buying an additional 22,564 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company's stock.

Wall Street Analysts Forecast Growth

ARVN has been the topic of a number of research analyst reports. HC Wainwright cut their price target on shares of Arvinas from $81.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday. Barclays decreased their target price on Arvinas from $32.00 to $16.00 and set an "overweight" rating for the company in a research note on Friday. Bank of America dropped their price target on Arvinas from $54.00 to $28.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th. Truist Financial reduced their price objective on shares of Arvinas from $65.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Finally, Oppenheimer downgraded shares of Arvinas from an "outperform" rating to a "market perform" rating in a research report on Tuesday, March 11th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Arvinas currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.82.

Insider Transactions at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the transaction, the insider now owns 159,121 shares of the company's stock, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares in the company, valued at $945,097.57. The trade was a 7.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,230 shares of company stock worth $769,402 in the last quarter. 5.23% of the stock is currently owned by corporate insiders.

Arvinas Trading Up 6.8 %

NASDAQ ARVN traded up $0.49 during trading hours on Friday, hitting $7.72. The company's stock had a trading volume of 8,593,139 shares, compared to its average volume of 1,251,025. The company has a market capitalization of $563.49 million, a PE ratio of -2.79 and a beta of 2.21. Arvinas, Inc. has a 52 week low of $5.94 and a 52 week high of $37.38. The company's 50-day simple moving average is $9.66 and its two-hundred day simple moving average is $17.44.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. The business's revenue was up 646.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.97) EPS. Research analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.